| BMR | Basal Metabolic Rate; 기초대사율 |
|---|---|
| CLO | 의복의 열차단 단위 1 CLO; 기온 21℃, 기습 50 %, 기류 5cm/sec에서 Metabolic Rate 50 Kcal/m2/Hr로 피부온도가 ... |
| L/S ratio | Lecithin/Sphingomyelin > 2이나 IRDS가 오는 경우 1. DM Mother ... |
| RMR | Resting Metabolic Rate = Resting Energy Expenditure |
| ADMR | average daily metabolic rate |
| metabolic encephalopathy | Encephalopathy characterised by memory loss, vertigo, and generalised weakness, due to metabolic brain disease including hypoxia, ischemia, hypoglycaemia, or secondary to other organ failure such as liver or kidney. (05 Mar 2000) |
|---|---|
| metabolic equivalent | The oxygen cost of energy expenditure measured at supine rest (1 MET = 3.5 ml O2 per kg of body weight per minute); multiples of MET are used to estimate the oxygen cost of activity, e.g., 3 to 5 METs for light work; more than 9 METs for heavy work. (05 Mar 2000) |
| metabolic indican | 1. <chemistry> A glucoside obtained from woad (indigo plant) and other plants, as a yellow or light brown sirup. It has a nauseous bitter taste, a decomposes or drying. By the action of acids, ferments, etc, it breaks down into sugar and indigo. It is the source of natural indigo. 2. <physiology> An indigo-forming substance, found in urine, and other animal fluids, and convertible into red and blue indigo (urrhodin and uroglaucin). Chemically, it is indoxyl sulphate of potash, C8H6NSO4K, and is derived from the indol formed in the alimentary canal. Synonym: uroxanthin. See: Indigo. Source: Websters Dictionary (01 Mar 1998) |
| metabolic mucinosis | Diffuse or pretibial myxoedema, lichen myxoedematosus, gargoylism, secondary mucinosis, degeneration in tumours, localised mucinosis, follicular, papular, plaque-like, focal, and myxoid or synovial cyst. Origin: mucin + G. -osis, condition (05 Mar 2000) |
| metabolic pool | The quantity of a given chemical compound or group of related compounds participating in metabolic reactions; may constitute only a portion of the total bodily content of such compounds. (05 Mar 2000) |
| compensated metabolic alkalosis | The retention of acid, primarily carbon dioxide by the lung and acid ions by the renal tubules, to reduce the effect on the pH of the blood of excess alkali produced by ingestion or metabolism of alkali-producing substances. (05 Mar 2000) |
| skin diseases, metabolic | Diseases of the skin associated with underlying metabolic disorders. (12 Dec 1998) |
| steroid metabolic clearance rate | A measure of the rate of metabolism of a given steroid within the body, usually expressed as liters of body fluid that contain the amount of steroid metabolised per day. (05 Mar 2000) |
| nutritional and metabolic diseases | A collective term for nutritional disorders (result of poor assimilation or utilization of food) and metabolic disorders (result of poor metabolism or inherited enzyme abnormality). (12 Dec 1998) |
| a1-trypsin inhibitor | A glycoprotein that is the major protease inhibitor of human serum, is synthesised in the liver, and is genetically polymorphic due to the presence of over 20 alleles; individuals appropriately homozygous are deficient in a1-trypsin and are predisposed to pulmonary emphysema and juvenile hepatic cirrhosis because of alterations in the amino acid and sialic acid components of the glycoprotein. A1-Antitrypsin also inhibits thrombin. Synonym: a1-trypsin inhibitor, human a1-proteinase inhibitor. (05 Mar 2000) |
| ACE inhibitor | <pharmacology> A group of antihypertensive medications that work by inhibiting an enzyme (angiotensin-converting enzyme) that is important in the regulation of blood pressure. Studies have also indicated that it may help prevent or slow the progression of kidney disease in patients with diabetes. Examples include: captopril, ramipril, enalapril, losartan potassium, bepridil and lisinopril. (12 Mar 1998) |
| aldose reductase inhibitor | <pharmacology> A class of drugs being studied as a way to prevent eye and nerve damage in people with diabetes. Aldose reductase is an enzyme that is normally present in the eye and in many other parts of the body. It helps change glucose (sugar) into a sugar alcohol called sorbitol. Too much sorbitol trapped in eye and nerve cells can damage these cells, leading to retinopathy and neuropathy. Drugs that prevent or slow (inhibit) the action of aldose reductase are being studied as a way to prevent or delay these complications of diabetes. (09 Oct 1997) |
| angiotensin-converting enzyme inhibitor | <pharmacology> A class of drugs used in the treatment of hypertension and heart failure. They exert their haemodynamic effect mainly by inhibiting the renin-angiotensin system and produce a reduction of peripheral arterial resistance. They also modulate sympathetic nervous system activity and increase prostaglandin synthesis. They cause mainly vasodilation and mild natriuresis without affecting heart rate and contractility. (14 Aug 2000) |
| aromatase inhibitor | Drugs, such as aminoglutethimide, that inhibit aromatase, an enzyme used in the synthesis of oestrogens. (05 Mar 2000) |
| beta-lactamase inhibitor | <pharmacology> Drugs such as clavulanic acid, which are used to inhibit bacterial beta-lactamases; often used with a penicillin or cephalosporin to overcome drug resistance. (05 Mar 2000) |